Misonidazole and hemibody irradiation in the palliation of widespread metastases. Final report of an RTOG study.
The radiation therapy oncology group conducted a phase I/II trial of hemibody irradiation combined with high-dose misonidazole in the management of metastatic solid tumors. Thirty-seven patients received 39 hemibody irradiation treatments, each preceded by 4 g/m2 or 5 g/m2 misonidazole orally. One fraction of 600 cGy was delivered to a half-body volume. Objective tumor response occurred in 21% of evaluable patients, including one complete response. Pain relief was documented in only 36%. Acute toxicity consisting of nausea and vomiting was significant; 54% of patients experienced severe or very severe reactions. Other toxicities were acceptable. The low response rate and high acute toxicity contraindicate the use of misonidazole with hemibody irradiation for palliation.
D000284:Administration, Oral; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D007958:Leukocyte Count; D008920:Misonidazole / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000532:radiotherapy*; D010148:Intractable Pain / Q000188:drug therapy; D013997:Time Factors
D008920:Misonidazole